Ropes & Gray represented Alnylam Pharmaceuticals in connection with a Rule 144A offering of $661.25 million aggregate principal amount of 0.00 percent convertible senior notes due 2028, including $86.25 million principal amount of convertible notes pursuant to the exercise in full of the initial purchasers’ option to purchase additional convertible notes. In addition, Ropes & Gray advised Alnylam in connection with the capped call transactions entered into concurrently with the offering. The transaction was announced on September 8, 2025, in a press release.
Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference therapeutics.
The team was led by capital markets partners Tristan VanDeventer and Zach Blume, and included tax partner David Saltzman, asset management partner Jeremy Liabo, and asset management counsel Lindsey Jones.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.